 Letters
https:/
/doi.org/10.1038/s41564-018-0157-z
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
Broadly neutralizing antibodies from human 
survivors target a conserved site in the Ebola  
virus glycoprotein HR2–MPER region
Andrew I. Flyak1,12, Natalia Kuzmina2,3, Charles D. Murin4,5, Christopher Bryan6, Edgar Davidson6, 
Pavlo Gilchuk7, Christopher P. Gulka8, Philipp A. Ilinykh2,3, Xiaoli Shen2,3, Kai Huang2,3,  
Palaniappan Ramanathan2,3, Hannah Turner4, Marnie L. Fusco5, Rebecca Lampley7, Nurgun Kose7, 
Hannah King7, Gopal Sapparapu7, Benjamin J. Doranz6, Thomas G. Ksiazek2,3, David W. Wright8,  
Erica Ollmann Saphire5,9, Andrew B. Ward4, Alexander Bukreyev  2,3,10* and James E. Crowe Jr
1,7,11*
1Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, USA. 2Department of Pathology, University of Texas 
Medical Branch, Galveston, TX, USA. 3Galveston National Laboratory, Galveston, TX, USA. 4Department of Integrative Structural and Computational 
Biology, The Scripps Research Institute, La Jolla, CA, USA. 5Department of Immunology and Microbial Science, The Scripps Research Institute,  
La Jolla, CA, USA. 6Integral Molecular, Inc., Philadelphia, PA, USA. 7Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA. 
8Department of Chemistry, Vanderbilt University Medical Center, Nashville, TN, USA. 9The Skaggs Institute for Chemical Biology, The Scripps Research 
Institute, La Jolla, CA, USA. 10Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX, USA. 11Department of 
Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA. 12Present address: Division of Biology and Biological Engineering, California Institute 
of Technology, Pasadena, CA, USA. *e-mail: alexander.bukreyev@utmb.edu; james.crowe@vanderbilt.edu
SUPPLEMENTARY INFORMATION
In the format provided by the authors and unedited.
NATuRE MICROBIOLOGy | www.nature.com/naturemicrobiology
 BROADLY NEUTRALIZING ANTIBODIES FROM HUMAN SURVIVORS TARGET A 
CONSERVED SITE IN THE EBOLA VIRUS GLYCOPROTEIN HR2/MPER REGION 
 
Andrew I. Flyak, Natalia Kuzmina, Charles D. Murin, Christopher Bryan, Edgar Davidson, 
Pavlo Gilchuk, Christopher P. Gulka, Philipp A. Ilinykh, Xiaoli Shen, Kai Huang, Palaniappan 
Ramanathan,  Hannah Turner, Marnie L. Fusco, Rebecca Lampley, Nurgun Kose, Hannah King, 
Gopal Sapparapu, Benjamin J. Doranz, Thomas G. Ksiazek, David W. Wright, Erica Ollmann 
Saphire, Andrew B. Ward, Alexander Bukreyev, and James E. Crowe, Jr. 
 
Correspondence to: james.crowe@vanderbilt.edu, alexander.bukreyev@utmb.edu. 
 
 
 
 
 
 
 
 
The file includes: 
 
Supplementary Table 1 
 
Supplementary Figures 1-4 
  
BDBV223 
BDBV317 
BDBV317 Fab 
BDBV340 
4G7 
D624A 
12   (7) 
64 (22) 
53 (11) 
23   (9) 
130   (2) 
H628A 
124 (17) 
57   (4) 
2   (1) 
68   (9) 
95 (29) 
D629A 
112 (23) 
117 (13) 
7   (0) 
91   (9) 
126   (1) 
D632A 
22 (15) 
57 (11) 
14   (2) 
138   (8) 
94 (11) 
K633A 
149 (41) 
23   (2) 
6   (3) 
127 (33) 
87 (31) 
 
 
 
Supplemental Table 1. Residues critical for BDBV mAb binding
Summary data for binding to EBOV GP are shown for BDBV mAbs, and anti-EBOV mAb c4G7. MAb 
reactivities for each alanine scan mutant are expressed as percent of binding value with wild-type GP, with 
ranges (half of the maximum value minus minimum value) in parentheses. Values are shaded in grey for 
critical residues. At least two replicate values were obtained for each experiment.
 mAb concentration (µg/mL)
Neutralization, %
10-4
10-2
100
102
104
-50
0
50
100
150
EBOV (Makona)
BDBV340  
BDBV223  
BDBV317  
10-4
10-2
100
102
104
RESTV (Plum Island)
mAb concentration (µg/mL)
Supplemental Figure 1. Neutralization activity of BDBV223, BDBV317 or BDBV340 against EBOV 
(Makona strain) or RESTV (Plum Island strain). Means ± SD of triplicates are shown.
 mAb BDBV223
mAb BDBV317 
Control mAb 
mAb BDBV340 
Body weight
Illness score
% body weight
Score
0
4
8
12
16
20
24
28
80
90
100
110
120
0
4
8
12
16
20
24
28
0
4
8
12
16
20
24
28
0
4
8
12
16
20
24
28
0
4
8
12
16
20
24
28
0
2
4
6
8
0
4
8
12
16
20
24
28
0
4
8
12
16
20
24
28
0
4
8
12
16
20
24
28
mAb BDBV223
mAb BDBV317 
Control mAb 
Body weight
Illness score
% body weight
Score
0
4
8
12
16
20
24
28
80
100
120
140
160
180
0
4
8
12
16
20
24
28
0
4
8
12
16
20
24
28
0
4
8
12
16
20
24
28
0
2
4
6
8
0
4
8
12
16
20
24
28
0
4
8
12
16
20
24
28
Days after challenge
Days after challenge
a Treatment of EBOV-inoculated mice
b Treatment of EBOV-inoculated guinea pigs
Control mAb 
Body weight
Illness score
% body weight
Score
Days after challenge
c Treatment of BDBV-inoculated ferrets
mAb BDBV223
0
4
8
12
16
20
24
28
85
90
95
100
105
110
0
4
8
12
16
20
24
28
0
4
8
12
16
20
24
28
1
2
3
4
0
4
8
12
16
20
24
28
Days after challenge
Days after challenge
Days after challenge
Days after challenge
Days after challenge
Days after challenge
Supplemental Figure 2. Post-exposure 
protection of EBOV-inoculated 
(a) mice [n = 5 animals per group],
(b) guinea pigs [n = 5 animals per group], or
(c) ferrets [n = 4 animals per group] 
with HR2/MPER-specific mAbs or a control 
2D22 mAb.
Percent change body weight curves, illness score 
curves are shown.
 ! " ! # $ $ %
%&
' ( )
* &
' ( )
+ &
' ( )
, $ &
' ( )
, - -
, - ,
, - $
, - %
, - .
, - /
, - *
, - 0
! " ! # $ %&
$ '( ) *
+ '( ) *
, '( ) *
%- '( ) *
%
.
.
%
.
%
%
.
-
%
.
$
%
.
/
%
.
0
%
.
+
%
.
&
0
1
2
3
4
5
6
7
! " # $ %
! %%
&'( ) *
+ '( ) *
, -. '( ) *
/ 0 0
/ 0 /
/ 0 %
/ 0 &
/ 0 1
/ 0 2
/ 0 +
/ 0 ,
3
6
7
3
6
9
12
3
6
9
12
Days after challenge
EBOV, log10 PFU/mL
mAb BDBV223
mAb BDBV317 
Control mAb 
0
1
2
3
4
5
6
7
8
0
1
2
3
4
5
6
7
8
BDBV, log10 PFU/mL
1
5
10
15
20
25
1
5
10
15
20
25
Days after challenge
Control mAb 
mAb BDBV223
Treatment of EBOV-inoculated guinea pigs
Treatment of BDBV-inoculated ferrets
Days after challenge
Days after challenge
Days after challenge
a
b
Supplemental Figure 3. The levels of viremia of individual guinea pigs infected with EBOV (a) and 
ferrets infected with BDBV (b) treated with the indicated mAbs. The limit of detection (1.3 log10) is 
indicated by the dotted line. For samples with no virus detected, the levels of viremia two-fold below the 
limit of detection were assigned. The horizontal lines indicate the mean values for each group. N = 5 
animals per group.
 BDBV223
BDBV317
BDBV340
Viruses:
Neutralization, %
mAb concentration (µg/mL)
BDBV D624N
BDBV
10-4 10-3 10-2 10-1
100
101
102
103
0
40
80
120
10-4 10-3 10-2 10-1
100
101
102
103
10-4 10-3 10-2 10-1
100
101
102
103
mAb concentration (µg/mL)
mAb concentration (µg/mL)
Supplemental Figure 4. Neutralization activity of BDBV223, BDBV317 or BDBV340 against wild-type 
BDBV (black) or BDBV D624N chimeric virus (red). Means ± SD of triplicates are shown.
